logo-loader

Tax boost for ImmuPharma investors

Last updated: 07:16 27 Jan 2015 GMT, First published: 08:16 27 Jan 2015 GMT

testubes_54c749b55c044

Drug developer ImmuPharma (LON:IMM) said it expects to qualify for the Enterprise Investment Scheme, which offers a range of tax reliefs to those who invest in the stock.  

The company said it had received advanced assurance from the HM Revenue and Customs that it will be included in the scheme.

Chairman Richard Warr said: “Qualifying for EIS gives ImmuPharma access to the broadest range of potential investors and investment funds."

Last week the AIM listed drug developer said it is ready to take its lead treatment into the final stage of clinical trials.

It has opted to work with a contract research organisation called Simbec-Orion to carry out phase-III studies on Lupuzor, for the auto-immune disease lupus, rather than tie-up with a traditional pharma company.

In doing so it hopes to maximise the return from what analysts say could be a blockbuster new product. 


ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug...

ImmuPharma PLC (AIM:IMM) chief executive Tim McCarthy provides an extensive update during an interview with Proactive's Stephen Gunnion, focusing on the financial, business, and portfolio developments of the company. McCarthy clarified that the company is in a strong financial position,...

3 weeks, 1 day ago